Model Finds Tisotumab Vedotin Cost-Effective for Recurrent or Metastatic Cervical Cancer in UK, Not China
A Markov survival model shows tisotumab vedotin is cost-effective for recurrent or metastatic cervical cancer in the UK but not ...
A Markov survival model shows tisotumab vedotin is cost-effective for recurrent or metastatic cervical cancer in the UK but not ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.